AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01406067 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Play group
Description: 12 double sessions (totally 24 treatment hours) in groups with up to 5 children. Different play activities were presented including techniques to activate resources of the child. These interventions give the children the opportunity to train pro-social interactions. Additionally up to 3 parent sessions were also included.
Study NCT02856750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin 300 mg three times daily x30 days
Study NCT01183273 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microlaparoscopic gastric bypass
Description: microlaparoscopic gastric bypass will be performed using standard of care procedure.
Study NCT01183273 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Surgery
Description: laparoscopic gastric bypass will be performed using standard of care procedure.
Study NCT01258569 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 12 mg oral 30-300 min pre-op then BID up to 7 days (or 15 doses)
Study NCT01127789 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Transcranial Direct Current Stimulation
Study NCT02628080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atovaquone
Description: Atovaquone has an EU marketing authorisation (held by Glaxo Wellcome UK Ltd) and is indicated for acute treatment of mild to moderate Pneumocystis pneumonia (PCP). It is also used in combination with proguanil for malaria prophylaxis.
Study NCT02686008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Patients will receive olaparib administered at 300 mg bid x 14 days orally
Study NCT03986593 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: cryoablation
Description: cryoablation of bone metastases by cone beam-CT image-guidance
Study NCT04416360 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview by psychologists
Description: Interviews for children / teenagers and parents :~* The questions encourage a narrative~* Repeated interviews: during confinement, at the end of confinement, and 3 months after the end of confinement~* Interviews carried out by videoconference, by trained psychologists not involved in the care process~Interview for referring caregivers: a single interview of approximately 45 minutes, 3 months post-confinement
Study NCT01484886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red blood cell transfusion
Description: 10cc/kg weight RBC transfusion as needed according to hemoglobin level
Study NCT01484886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red blood cell transfusion
Description: 10cc/kg body weight RBC will be transfused for hemoglobin under 9.5 for biventricular repairs and under 12 for single ventricle palliations.
Study NCT01757717 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ir-192 high dose rate (HDR)
Description: Patients will be followed at 2 months (+/- 2 weeks) post-treatment and then approximately every 3 months (+/- 2 weeks) until approximately 11 months of follow up. They will be evaluated for pain referable to the treated site, clinical and radiographic evidence of local progression, and treatment related toxicity. Thereafter, patients will be followed as clinically indicated.
Study NCT04353778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyridostigmine
Description: Eight weeks of low-dose pyridostigmine
Study NCT04353778 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: matching placebo x 8 weeks
Study NCT03426020 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral midazolam
Description: 0.5 mg/kg oral midazolam administered 20 minutes before induction
Study NCT03426020 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Film http://www.animaturk.com/animasyon/suko-ameliyat-oluyor
Description: patients will be watched a short movie (at URL: http://www.animaturk.com/animasyon/suko-ameliyat-oluyor ) 20 minutes before induction.
Study NCT03426020 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Play game (PC fishing game)
Description: Patients will be played a simple PC game (a fishing game) 20 minutes before induction
Study NCT03321448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMTP1-ICG
Description: Detection of SLN
Study NCT03321448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ICG
Description: Detection of SLN
Study NCT00841737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducational group
Description: The intervention group receive weekly a psychoeducational group during 12 weeks run by 2 nurses. The program have a structures contend.
Study NCT00841737 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: In the control group the depression is treated as usual with the conventional treatment.
Study NCT03922854 — intervention group
Intervention type: OTHER
Intervention: Non-interventional data collection only
Description: There is no clinical intervention. This study is just capturing data from devices used part of routine clinical care. The results of this data collection will be analysed to inform study results.
Study NCT03569852 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restrictive Feeding
Description: Volunteers will adhere to a form of time restrictive feeding, 16 hours fasting and 8 hours eating per day.
Study NCT03569852 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional Eating Pattern
Description: Volunteers will adhere to a more traditional eating pattern, 12 hours fasted and 12 hours eating per day.
Study NCT00440726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Intravenous on days 1, 4, 8 and 11. Dose assigned at study entry.
Study NCT00440726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 10 mg/m2/day divided BID, oral administration for 14 days.
Study NCT00440726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-asparaginase
Description: 2500 IU/m2/day, intramuscular injection on Days 2, 8, 15 and 22
Study NCT00440726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 60 mg/m2/day IV over 15 minutes on Day 1
Study NCT00440726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given intrathecally on Day 1 of course 1 at the dose defined by age below.~* 30 mg for patients age 1-1.99~* 50 mg for patients age 2-2.99~* 70 mg for patients >3 years of age
Study NCT00440726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given intrathecally to all patients who are CNS 1 at study entry on Day 15 at the dose defined by age below.~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients >9 years of age
Study NCT00440726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.5 mg/m2/dose IV push (maximum single dose 2 mg) on Days 1, 8, 15 and 22.
Study NCT00440726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple IT Therapy
Description: Triple IT therapy will be given intrathecally on Day 8, 15, and 22 for patients who are CNS 2 and CNS 3 at study entry. Regimen/dosing as follows:~Methotrexate-~* \<2 years: 8 mg~* 2 - \<3 y: 10 mg~* 3 - \<9 y: 12 mg~* >=9 y: 15 mg~Cytarabine:~* \<2 years: 16 mg~* 2 - \<3 y: 20 mg~* 3 - \<9 y: 24 mg~* >=9 y: 30 mg~Hydrocortisone:~* \<2 years: 8 mg~* 2 - \<3 y: 10 mg~* 3 - \<9 y: 12 mg~* >=9 y: 15 mg
Study NCT01482910 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Description: Participants in the VEGF Trap-Eye group received intravitreal injections every 8 weeks following a loading phase with injections given every 4 weeks for an overall treatment period of 48 weeks. Additionally, sham PDT treatments was administered as needed.
Study NCT04353778 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: non-invasive vagal nerve stimulation
Description: stimulation of the vagus nerve
Study NCT01482910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Visudyne
Description: Participants in the PDT group (Visudyne group) received Visudyne as needed. Additionally, sham IVT injections was administered until week 28. Thereafter, subjects in the PDT group received active (= no sham) VEGF Trap-Eye treatment until week 48.
Study NCT02656628 — intervention group
Intervention type: DEVICE
Intervention: Dynamic Locking Screw 3.7mm and 5.0mm
Description: Treatment with DLS and locked plate constructs (small or large fragments)
Study NCT03803969 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ConfirmRx (Insertable Cardiac Monitor)
Description: This study is designed to characterise the safety and performance of the ConfirmRx device by assessing quality of signal attained from the device with changes in posture and physical activity at implant and 30days post procedure. The study is also intended to assess gross migrations of the device at 30days post implant.
Study NCT03818035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Participants will receive 100 mg guselkumab subcutaneously at Weeks 0, 4, 12 and 20 (group 1), at weeks 28, 36, 44, 52, 60 (group 2a and 2c), and at weeks 36 and 52 (group 2b). Group 2d and 3c are the re-treatment groups and will receive three injections after loss of disease control.
Study NCT04464213 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single dose experiments
Description: In single dose experiments, after clean the diabetic foot ulcer, paint the Human placental mesenchymal stem cells gel on the wound, each patient only receive treatment once time.
Study NCT04464213 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-dose experiments
Description: In multi-dose experiments, after clean the diabetic foot ulcer, paint the Human placental mesenchymal stem cells gel on the wound, each patient receive treatment on six consecutive days.
Study NCT03658369 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lanconone®
Description: 2 capsules
Study NCT03658369 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Methyl crystalline cellulose
Description: 2 Capsules
Study NCT04210466 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance & Commitment Therapy + Compassion (COMP.ACT)
Description: 8 sessions, 2h each. Intervention includes meditation exercises, behavioral exercises, group discussions, and the structure is the following Session 1: INTRODUCTION: control is the problem Session 2: THE BODY AS PRESENT: promoting body awareness through mindfulness Session 3: COMPASSION I: from self-criticism to self-care Session 4: COMPASSION II: the body as an anchor to self-compassion Session 5: ACCEPTANCE: there is more to accept than just pain Session 6: (RE)DISCOVERING VALUES: in search of a valued life Session 7: ACT NOW: from values to committed action Session 8: CARRY ON AFTER COMP.ACT: program summary
Study NCT04210466 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and Commitment Therapy (ACT)
Description: 8 sessions, 2h each. Intervention includes meditation exercises, behavioral exercises, group discussions, and the structure is the following Session 1: INTRODUCTION: control is the problem Session 2: THE BODY AS PRESENT: promoting body awareness through mindfulness Session 3: Q\&A 1 Session 4: Q\&A 2 Session 5: ACCEPTANCE: there is more to accept than just pain Session 6: (RE)DISCOVERING VALUES: in search of a valued life Session 7: ACT NOW: from values to committed action Session 8: CARRY ON AFTER COMP.ACT: program summary
Study NCT00173862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, Ifosfamide
Study NCT03558347 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: short implants with splinted crowns
Description: 7 mm short implants (CONELOG® Implant System), individualized titanium abutments, splinted lithium disilicate crowns
Study NCT03558347 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: short implants with non-splinted crowns
Description: 7 mm short implants (CONELOG® Implant System), individualized titanium abutments, non-splinted lithium disilicate crowns
Study NCT01846286 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Five questionnaires about pain and symptoms, each taking approximately 25 - 50 minutes to complete
Study NCT01846286 — intervention group
Intervention type: OTHER
Intervention: Quantitative Sensory Testing
Description: Tests measure sensitivity to touch, coolness, warmth, hot/cold feeling, and pin pricks. The sensory tests will take about 30 minutes to 1 hour to complete.
Study NCT02900703 — intervention group
Intervention type: BIOLOGICAL
Intervention: stool samples
Study NCT00882141 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet modification
Description: Weight loss sessions are held by a registered dietitian for 1 hour once a week for 6-9 months; recommended caloric intake to elicit a weight loss of approximately 0.2-0.4 kg per week
Study NCT00882141 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Treadmills and other aerobic exercise equipment 3 times a week for 6-9 months, beginning at low levels of VO2max and progressing in duration and intensity to more than 75% VO2max for 45 minutes
Study NCT02945956 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Entecavir
Description: The subjects will be taking 1 Entecavir tablet per day for 96 weeks.
Study NCT02945956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir + Fuzheng Huayu
Description: The subjects will be taking 1 Entecavir tablet per day and 4 Fuzheng Huayu tablets three times a day for 96 weeks.
Study NCT01046695 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS Unit
Description: TENS is a method of pain relief that uses a battery operated electronic device with cutaneously applied electrodes that deliver electrical signals to peripheral nerves through the intact skin. The TENS Unit is a low voltage system that will only be used to a level to create alternative to pain sensation and will not create muscle response.
Study NCT00510185 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: systematic coronary intervention
Description: Coronary angiography within 72 hrs
Study NCT00510185 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: coronary intervention only for cases refractory to medical therapy
Description: Initially conservative treatment with coronary angiography only for recurrent ischemia
Study NCT04282031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-1178
Description: BPI-1178 once daily on Days 1 to 21 of a 28-day cycle
Study NCT04483401 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to Occupational Performance (CO-OP)
Description: Intervention: CO-OP is a cognitive approach to solving functional motor problems (Polatajko et al., 2001b). Therapists teach children a global problem solving strategy (Goal-Plan-Do-Check) as a framework for developing specific strategies for overcoming motor problems; these strategies are determined after a dynamic performance analysis by the therapist to determine where the breakdown is in performing the task. CO-OP intervention will be administered by occupational therapists who have been trained in the CO-OP approach. Children will be seen once weekly for one hour over 12 weeks at as per published protocol (Polatajko et al., 2001b). Parents or caregivers will be encouraged to attend treatment sessions so that therapists can instruct them how to facilitate strategy use between treatment sessions. Children will select three functional motor goals to be addressed over the course of treatment, rating their performance and satisfaction of these goals pre- and post-intervention.
Study NCT04958460 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administrated 1 packet of maltodextrin (as placebo of Bf-688) in the morning and evening
Study NCT04958460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BF688
Description: Administrated 1 pack each morning and evening (5×109 CFUs per day)
Study NCT04571671 — intervention group
Intervention type: OTHER
Intervention: Collect retrospectively data
Description: Analyse the incidence of Mullerian anomalies in these populations
Study NCT02855918 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample for genetic purpose
Description: All the participants will performed the same evaluations and blood analysis :~* A clinical assessment by psychiatrist~* Self report questionnaires for the assessment of a potential mood disorder and history of SB, moral/physical pain, personality traits...~* A neuropsychological assessment for the evaluations of cognitive performances~* A routine blood sampling to the realization of a standard blood test~* A specific blood sampling (PAXgene® tubes) to extract total RNA of blood cells and measure the expression of ADARS RNA and editing of the PDE8A transcript.
Study NCT03818035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Injection
Description: Participants of group 2b will receive matching placebo injection subcutaneously at weeks 28, 44 and 60.
Study NCT01358877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-Fluorouracil will be administered as per the schedule specified in the respective arm.
Study NCT01358877 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-Fluorouracil
Description: 5-Fluorouracil will be administered as per the schedule specified in the respective arm.
Study NCT01358877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered as per the schedule specified in the respective arm.
Study NCT01358877 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin will be administered as per the schedule specified in the respective arm.
Study NCT01358877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered as per the schedule specified in the respective arm.
Study NCT01358877 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered as per the schedule specified in the respective arm.
Study NCT01358877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered as per the schedule specified in the respective arm.
Study NCT01358877 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel will be administered as per the schedule specified in the respective arm.
Study NCT01358877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin will be administered as per the schedule specified in the respective arm.
Study NCT01358877 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin will be administered as per the schedule specified in the respective arm.
Study NCT01358877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin will be administered as per the schedule specified in the respective arm.
Study NCT01358877 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epirubicin
Description: Epirubicin will be administered as per the schedule specified in the respective arm.
Study NCT01358877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered as per the schedule specified in the respective arm.
Study NCT01358877 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel will be administered as per the schedule specified in the respective arm.
Study NCT01358877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab will be administered as per the schedule specified in the respective arm.
Study NCT01358877 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as per the schedule specified in the respective arm.
Study NCT01358877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab will be administered as per the schedule specified in the respective arm.
Study NCT01358877 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab will be administered as per the schedule specified in the respective arm.
Study NCT04282031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant 500mg intramuscularly on Days 1 and 15 of Cycle 1, and on Day 1 of Cycle 2 and beyond
Study NCT04282031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole 2.5 mg once daily of a 28-day cycle
Study NCT04282031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-1178
Description: BPI-1178 once daily of a 28-day cycle
Study NCT01717131 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery for standard axillary node dissection
Study NCT01717131 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No axillary lymph node dissection
Description: No surgery on axillary lymph node
Study NCT03814200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Single i.v. infusion of 100 mL saline 0.9% for 30 min